Interferon gamma biosimilar (Pharmaclon)

干扰素γ生物类似药 (Pharmaclon)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInterferon gamma biosimilar (Pharmaclon)
Drug Alias Name干扰素γ生物仿制药 (Pharmaclon)Ingaron
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionInterferon gamma receptor stimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsImmunostimulants
TargetsInterferon gamma receptor
Therapy Area/IndicationsProstatitisRespiratory Distress Syndrome, NewbornNeoplasms +[15] 
Global Approved IndicationsProstatitisRespiratory Distress Syndrome, NewbornNeoplasms +[11] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryRussian Federation
Original Approved Date2011/01/01
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPharmaclon
China Registration ClassN/A

Develop Information

Active CompaniesPharmaclon
Inactive CompaniesSPP Pharmaclon Ltd
Active IndicationsProstatitisRespiratory Distress Syndrome, NewbornNeoplasms +[11] 
Inactive IndicationsLentivirus InfectionsRNA Virus InfectionsPapillomavirus Infections +[4] 

Other Information

ATC CodeL03AB03
Related LinksN/A